News
CMS Finalizes Policy to Limit Co-Pay Accumulator Programs
Industry News & Research
On April 18, 2019, the Centers for Medicare and Medicaid Services (CMS) released the final Notice of Benefit and Payment Parameters Rule…
Sangamo and Pfizer Announce Interim Trial Data for Hemophilia A Gene Therapy
Industry News & Research
Sangamo Therapeutics, Inc and Pfizer, Inc. recently announced interim data from the phase 1/2 Alta study designed to evaluate SB-525, the company’s…
New Financial and Patient Support Services for People Living With Hemophilia
Industry News & Research
The Patient Access Network (PAN) Foundation and the National Hemophilia Foundation (NHF) announced they are launching a new alliance to offer a…
New CME-Accredited Activity on Evaluating Patients with Suspected VWD
Industry News & Research
Register today for a new CME-accredited educational activity on “Recognizing and Remediating von Willebrand Disease – A Case Study in Collaborative Care,” provided by Haymarket…
Cell-based Gene Therapy May Offer Long-term Treatment for Hemophilia A, Mouse Study Suggests
Industry News & Research
Cell therapy with endothelial progenitor cells and stem cells genetically engineered to produce a functional clotting factor VIII (FVIII) may provide a…
uniQure Announces Updated Data from Phase 2B Dose Confirmation of AMT-061
Industry News & Research
uniQure is excited to announce that updated data from their Phase 2B dose-confirmation study of AMT-061, an investigational gene therapy for the…
NHF and Partners Announce Innovative Infusion Logging Tool
Industry News & Research
The National Hemophilia Foundation (NHF) has announced a new two-year pilot program that aims to improve the efficacy of patient infusion logs…
Online Health Information: Is It Reliable?
Industry News & Research
by: Paul Clement It’s an exciting time for people with inhibitors. In addition to bypassing agents, new products may prevent or control…
PT Study Focuses on Comprehensive Survey of Physical Activities Risks for 101 Activities
Industry News & Research
Physical therapists (PTs) at hemophilia treatment centers (HTCs) often consult with hemophilia patients about engaging in new physical activities like exercise, team/individual…
Catalyst Reports Positive Trial Updates for Subcutaneous Therapy for Hemophilia
Industry News & Research
Catalyst Biosciences, Inc recently reported updated interim data from their phase 2/3, multinational clinical study of marzeptacog alfa (MarzAA), a subcutaneous (administered…
Takeda Completes Acquisition of Shire
Industry News & Research
Takeda Pharmaceutical Company Limited recently announced the completion of its acquisition of Shire plc on January 8, 2019. The acquisition was approved…
Sangamo Announces First Patient Treated in Hemophilia B Gene Therapy Trial
Industry News & Research
Sangamo Therapeutics, Inc. recently announced it has treated the first patient in a Phase 1/2 clinical trial evaluating SB-FIX, the company’s investigational…
Two New MASAC Documents Issued
Industry News & Research
The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council has issued two new documents on November 21, 2018 that were approved…
Inhibitor Chapter Updated in Nurses’ Guide to Bleeding Disorders
Industry News & Research
The National Hemophilia Foundation’s (NHF’s) Nursing Working Group continues to revise and expand its Nurses’ Guide to Bleeding Disorders (NGBD). The latest chapter that has…
Results of Bayer’s PROTECT VIII Extension Study Announced
Industry News & Research
Bayer announced findings from an analysis of the PROTECT VIII extension study. This study found that long-term safety and efficacy was consistent…
Bioverativ and Sobi Release Long-Term Study Results for Extended Half-Life Therapies
Industry News & Research
Swedish Orphan Biovitrum AB (Sobi) and Bioverativ Inc. announced the results of ASPIRE and B-YOND, the most comprehensive long-term studies of extended…
Bayer Receives FDA Approval for Jivi, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen
Industry News & Research
Jivi’s extended half-life allows for twice-weekly initial dosing and may be adjusted to every five days and further individually adjusted to less…
They Thought Hemophilia Was a ‘Lifelong Thing.’ They May Be Wrong.
Industry News & Research
In a recent New York Times article by Gina Kolata, scientists are edging closer to defeating a longtime enemy of human health:…
UniQure Reports Successful Delivery of FIX Gene Despite Antibodies
Industry News & Research
UniQure presented new hemophilia B clinical trial data on May 19, 2018 at the American Society of Gene and Cell Therapy (ASGCT)…
HTC Investigators Look at Rates of Cardiovascular Disease in Hemophilia Patients
Industry News & Research
Because of their lower factor levels, hemophilia patients are generally thought to be better protected from cardiovascular disease (CVD). To determine whether…
Prophylaxis Study Results for Boys with Severe Hemophilia A
Industry News & Research
A group of Canadian researchers recently published findings from a clinical study on the use of prophylaxis with a standard half-life recombinant…
New Study on Aging, VWF Levels and Bleeding Risk
Industry News & Research
Investigators from the Hemophilia Center of Western Pennsylvania (HCWP) recently looked at the effect of aging on von Willebrand factor (VWF) levels…